|
|||||
|
|
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase |
|
| Authors: | Dennis Kim Nada Hamad Hong Gi Lee Suzanne Kamel‐Reid Jeffrey H Lipton |
| Institution: | 1. Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, University of Toronto, Ontario, Canada;2. Department of Pathology, Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada |
| Abstract: | |
| Keywords: | |